JP Morgan Chase
PHAS

JP Morgan Chase’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

JP Morgan Chase’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17
Closed – – 7352
2022
Q3 		$0 Hold
17
– – ﹤0.01% 7113
2022
Q2 		$0 Sell
17
-2,000
-99% -$1.92K ﹤0.01% 7155
2022
Q1 		$3K Buy
2,017
+2,000
+11,765% +$3.24K ﹤0.01% 6404
2021
Q4 		$0 Hold
17
– – ﹤0.01% 7184
2021
Q3 		$0 Sell
17
-76,589
-100% -$256K ﹤0.01% 6985
2021
Q2 		$285K Buy
76,606
+5,732
+8% +$19.1K ﹤0.01% 5046
2021
Q1 		$245K Buy
70,874
+29,868
+73% +$121K ﹤0.01% 5066
2020
Q4 		$138K Buy
41,006
+35,284
+617% +$126K ﹤0.01% 4919
2020
Q3 		$20K Buy
5,722
+673
+13% +$2.71K ﹤0.01% 5150
2020
Q2 		$23K Buy
5,049
+648
+15% +$2.87K ﹤0.01% 5012
2020
Q1 		$15K Sell
4,401
-1,604
-27% -$7.34K ﹤0.01% 5004
2019
Q4 		$36K Buy
6,005
+1,507
+34% +$6.21K ﹤0.01% 5220
2019
Q3 		$19K Buy
4,498
+729
+19% +$5.81K ﹤0.01% 5422
2019
Q2 		$48K Buy
+3,769
New +$46.2K ﹤0.01% 5186

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

JP Morgan Chase's PHAS Position: Q4 2022 in Review

JP Morgan Chase sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 17 shares.

JP Morgan Chase first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $285K in Q2 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • JP Morgan Chase reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Chase sold 17 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • JP Morgan Chase first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • JP Morgan Chase's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $285K in Q2 2021.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.